A method for selecting a female breast cancer patient for AT<SUB>1</SUB> receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT<SUB>1</SUB> receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT<SUB>1</SUB> receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.
